
OrthoPediatrics Corp. KIDS
$ 15.82
-2.29%
Annual report 2025
added 03-04-2026
OrthoPediatrics Corp. General and Administrative Expenses 2011-2026 | KIDS
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses OrthoPediatrics Corp.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 120 M | 103 M | 73.3 M | 57.9 M | 46.1 M | 38.3 M | 26.7 M | 20.9 M | 17 M | 13.6 M | 11.4 M | 9.88 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 120 M | 9.88 M | 44.8 M |
Quarterly General and Administrative Expenses OrthoPediatrics Corp.
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 30.4 M | 30.3 M | 26.3 M | 27.3 M | 24.7 M | 18 M | 19.1 M | 17.2 M | - | 15.1 M | 14.5 M | 13.2 M | - | 11 M | 11.1 M | 12 M | - | 9.82 M | 10.6 M | 7.88 M | - | 7.27 M | 6.57 M | 5.61 M | - | 4.88 M | 5.5 M | 6.02 M | - | 3.49 M | 3.42 M | 3.37 M | - | 2.89 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 30.4 M | 2.89 M | 12.9 M |
General and Administrative Expenses of other stocks in the Medical devices industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
GenMark Diagnostics, Inc.
GNMK
|
25.6 M | - | - | $ 1.77 B | ||
|
AdaptHealth Corp.
AHCO
|
382 M | $ 13.08 | 2.19 % | $ 1.77 B | ||
|
Allied Healthcare Products
AHPI
|
7.11 M | - | 3.58 % | $ 2.21 M | ||
|
BioSig Technologies
BSGM
|
67.5 M | - | 37.08 % | $ 85.7 M | ||
|
Avinger
AVGR
|
14.1 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
40.2 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
15.1 M | - | 1.37 % | $ 20.5 M | ||
|
BIOLASE
BIOL
|
10.2 M | - | -13.19 % | $ 166 K | ||
|
Obalon Therapeutics, Inc.
OBLN
|
8.78 M | - | -5.86 % | $ 30.6 M | ||
|
Conformis
CFMS
|
28.8 M | - | - | $ 16.4 M | ||
|
Cytosorbents Corporation
CTSO
|
35.6 M | $ 0.61 | -2.58 % | $ 38 M | ||
|
Apollo Endosurgery
APEN
|
20.6 M | - | - | $ 475 M | ||
|
EDAP TMS S.A.
EDAP
|
5.9 M | $ 3.22 | - | $ 121 M | ||
|
Cardiovascular Systems
CSII
|
171 M | - | 0.15 % | $ 844 M | ||
|
ClearPoint Neuro
CLPT
|
16.5 M | $ 11.21 | -4.84 % | $ 317 M | ||
|
Globus Medical
GMED
|
1.18 B | $ 93.7 | -1.24 % | $ 12.7 B | ||
|
Helius Medical Technologies
HSDT
|
9.27 M | $ 2.12 | -1.85 % | $ 1.29 M | ||
|
Dynatronics Corporation
DYNT
|
8.46 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
54.3 M | - | - | $ 10.2 M | ||
|
CryoLife, Inc.
CRY
|
141 M | - | -4.14 % | $ 702 M | ||
|
Electromed
ELMD
|
39.3 M | $ 26.0 | -1.48 % | $ 220 M | ||
|
Second Sight Medical Products
EYES
|
1.11 M | - | -0.97 % | $ 54.4 M | ||
|
GBS
GBS
|
8.88 M | - | -0.57 % | $ 7.12 M | ||
|
Soliton, Inc.
SOLY
|
8.46 M | - | -1.42 % | $ 435 M | ||
|
LivaNova PLC
LIVN
|
549 M | $ 63.41 | -1.23 % | $ 3.46 B | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.88 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
8.5 M | - | 0.03 % | $ 1.58 B | ||
|
LENSAR
LNSR
|
45.2 M | $ 5.21 | 2.36 % | $ 62.3 M | ||
|
Misonix, Inc.
MSON
|
18 M | - | - | $ 462 M | ||
|
Pulmonx Corporation
LUNG
|
101 M | $ 1.28 | 0.79 % | $ 52.1 M | ||
|
Neovasc
NVCN
|
14.7 M | - | - | $ 111 M | ||
|
Butterfly Network
BFLY
|
39.8 M | $ 5.48 | 2.81 % | $ 1.16 B | ||
|
Intersect ENT, Inc.
XENT
|
98.6 M | - | - | $ 955 M | ||
|
Insulet Corporation
PODD
|
1.16 B | $ 188.31 | -0.66 % | $ 13.2 B | ||
|
Delcath Systems
DCTH
|
43.5 M | $ 10.84 | - | $ 388 M | ||
|
IRIDEX Corporation
IRIX
|
7.73 M | $ 1.08 | 1.89 % | $ 18.3 M | ||
|
CONMED Corporation
CNMD
|
132 M | $ 37.87 | -1.23 % | $ 1.18 B | ||
|
Inspire Medical Systems
INSP
|
625 M | $ 55.07 | -2.2 % | $ 1.62 B | ||
|
Sintx Technologies
SINT
|
6.2 M | $ 2.35 | -4.86 % | $ 6.52 M | ||
|
Integer Holdings Corporation
ITGR
|
212 M | $ 85.35 | -0.78 % | $ 2.96 B | ||
|
PAVmed
PAVM
|
16.2 M | $ 8.4 | -6.67 % | $ 5.63 M | ||
|
Invacare Corporation
IVC
|
227 M | - | - | $ 24.7 M | ||
|
Edwards Lifesciences Corporation
EW
|
2.09 B | $ 83.46 | -0.94 % | $ 48.8 B | ||
|
Stryker Corporation
SYK
|
8.65 B | $ 329.01 | 0.46 % | $ 126 B | ||
|
MiMedx Group
MDXG
|
56.5 M | $ 3.34 | -2.62 % | $ 494 M | ||
|
Tactile Systems Technology
TCMD
|
88.7 M | $ 24.24 | -3.31 % | $ 554 M | ||
|
Nevro Corp.
NVRO
|
310 M | - | - | $ 217 M |